A strong team with experience and know-how


Dr. Walter von Horstig - Vorstand
Attila Strauss

Attila Stauss

Mr Attila Strauss studied International Trade Management (B.A.) and Information Technology with a focus on IT Security (M.Sc.) in Ingolstadt and Bochum. Before joining the group of companies, Mr Strauss worked for well-known companies in the field of process optimisation. At M1 Kliniken AG he is responsible for the areas of administration, finance, IT and international expansion with a focus on Eastern Europe.

Kilian Brenske - Vorstand
Kilian Brenske

Kilian Brenske

Mr Kilian Brenske studied business administration in Berlin and graduated with a Master of Science in Management and Innovation.

Mr Kilian Brenske has been with the company since 2016 and has been responsible for all major business areas in Germany and abroad during this time. In particular, he built up the medical skin care brand M1 Select, significantly improved the productivity of the sites and most recently led the international expansion. With the addition of Mr. Kilian Brenske to the Management Board, M1 Kliniken AG is underlining its strategic goal of international growth. Mr Brenske will be responsible for national and international expansion, marketing, purchasing and sales.



Uwe Zimdars
Prof. Dr. med. Dirk Hempel
Prof. Dr. Dr. Sabine Meck

Latest news

| Investor News

  • Management is open to interested parties
  • Valuations in the peer group of up to 30 times the annual EBITDA
  • M1 Kliniken AG expects EBITDA of over EUR 27 million in 2024

| Investor News

By acquiring the German Nutri Care GmbH and its wholly-owned subsidiary, the Dutch online pharmacy "Direct Apotheke Venlo B.V.," M1 Kliniken AG (ISIN: DE000A0STSQ8) taps into a significant growth field and expands the value chain of its health services. Direct Apotheke Venlo B.V., based in Maasbree (NL), is one of the rapidly growing providers in the online pharmacy business for aesthetic pharmaceuticals, with current core markets in Germany and the Netherlands. In the fiscal year 2022, the company recorded double-digit million-euro revenues and continues on a growth trajectory.

| Investor News

  • Group sales increase by over 10% to EUR 236.6 million in the first nine months of the 2023 financial year (previous year: EUR 214.2 million).

  • Group EBITDA increases by over 55% from EUR 10.9 million to EUR 16.9 million.

  • The operating result (Group EBIT) increases by over 98% to EUR 12.9 million (previous year: EUR 6.5 million).

  • Beauty segment: sales increase of 28.5% to EUR 53.2 million (previous year: EUR 41.4 million) and sharp rise in the Beauty EBIT margin from 8.2% to 23.5%

| Investor News

  • 20th Location outside Germany opened in Bucharest, Romania
  • Break-even expected for foreign locations within the next 12 months
  • Subsidiary established in the USA: Market entry into the world's largest market for beauty medicine expected in 2024